Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of “Moderate Buy” by Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $21.8333.

Several research firms have weighed in on TBPH. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. B. Riley Financial boosted their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. TD Cowen boosted their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. HC Wainwright boosted their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, BTIG Research reiterated a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after acquiring an additional 54,152 shares during the period. State Street Corp boosted its holdings in shares of Theravance Biopharma by 4.4% during the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after acquiring an additional 45,987 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Theravance Biopharma by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 124,658 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after acquiring an additional 40,734 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Theravance Biopharma during the third quarter valued at $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 0.9%

Shares of NASDAQ:TBPH opened at $16.64 on Friday. The company has a fifty day simple moving average of $16.46 and a 200 day simple moving average of $17.47. The firm has a market cap of $857.84 million, a PE ratio of 7.56 and a beta of 0.17. Theravance Biopharma has a 12-month low of $10.42 and a 12-month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million for the quarter. As a group, equities research analysts forecast that Theravance Biopharma will post 1.54 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.